Galafold 123 MG
Ended Awarded
- Contract number
- 36C24525N0879
- Awardee
-
Amicus Therapeutics US, LLC UEI KLJFGENKMD89
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $21,891
Award facts
- Contract value 100% obligated
- $21,891.21 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19104, USA
Award details come from SAM.gov/FPDS.
About this award
The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 5 (VISN 5), awarded a delivery order to Amicus Therapeutics US, LLC for the supply of Galafold 123 mg on August 6, 2025, with a ceiling value of $21,891.21. This firm fixed-price delivery order, which is expected to be completed by August 8, 2025, represents a task order under the parent Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB). The award was made without a set-aside designation and will be performed in Philadelphia, Pennsylvania. Galafold (migalastat) is an enzyme replacement therapy used to treat Fabry disease, a rare genetic disorder, and this delivery order supports the VA's mission to provide specialized pharmaceutical treatments to veterans.
Amicus Therapeutics US, LLC, a biopharmaceutical company specializing in treatments for rare genetic diseases, holds a significant GSA multiple-award contract valued at approximately $13 million through August 31, 2029, which serves as the parent vehicle for this delivery order. The company has established itself as a key supplier of Galafold to the VA across multiple VISN regions nationwide. As the prime contractor, Amicus Therapeutics US, LLC will deliver the pharmaceutical product directly with no identified subcontractor involvement. This delivery order is consistent with the company's pattern of providing short-term, urgent pharmaceutical supplies to support VA healthcare facilities in delivering specialized medications to veterans.
Quick answers
Who was awarded contract 36C24525N0879?
36C24525N0879 was awarded to Amicus Therapeutics US, LLC by Veterans Integrated Service Network 5 (Veterans Health Administration) on August 6, 2025.
How much is contract 36C24525N0879 worth?
The government has obligated $21,891 on 36C24525N0879.
Is contract 36C24525N0879 an order under another contract?
Yes. 36C24525N0879 is a delivery order under 36F79724D0185, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24525N0879 competed?
The extent of competition for 36C24525N0879 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award